Related Experiment Video
Updated: Jul 14, 2025
A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces
Published on: January 7, 2020
Construction of "Coral" SERS sensor for ultrasensitive and rapid detection of harmful component macrophage migration
Yiran Zhu1, Yang Sun2, Yang Shi3
1Department of Orthopedics, Sir Run Run Hospital, Nanjing Medical University, Nanjing, PR China.
Abstract:
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory factor produced by residual red blood cell lysis, which can significantly influence the curative effect of Platelet-rich plasma (PRP) therapy used for osteoarthritis (OA) treatment. In this study, we proposed a novel approach for detecting the concentration of MIF in PRP using a dopamine-coated antibody-Au (core)-Ag (shell)-SERS sensor, which enables ultrasensitive and rapid detection of MIF. The best experimental conditions have a detection limit of only 90.05 pg/mL and a good linear relationship between 1-5000 ng/mL. In 40 PRP samples collected from actual clinical patients, we detected MIF concentrations ranging from 2.0-3.6 ng/mL. This indicated that the Coral SERS sensor not only allows for results highly consistent with the traditional ELISA method, but also costs less ($0.40-$0.70), needs shorter testing time (integration time is only 10s), and consumes less PRP that can greatly improve the sample quality and maximize the curative effect in clinical applications for OA treatment with PRP.
Insights
A novel SERS sensor detects macrophage migration inhibitory factor (MIF) in Platelet-rich plasma (PRP) for osteoarthritis (OA) treatment. This ultrasensitive method improves PRP therapy efficacy by enabling rapid, cost-effective MIF concentration analysis.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Immunology
Background:
- Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine impacting Platelet-rich plasma (PRP) therapy outcomes for osteoarthritis (OA).
- Accurate and rapid MIF detection in PRP is crucial for optimizing OA treatment efficacy.
Purpose of the Study:
- To develop and validate a novel Surface-Enhanced Raman Spectroscopy (SERS) sensor for ultrasensitive and rapid detection of MIF in clinical PRP samples.
- To evaluate the sensor's performance against traditional methods and assess its potential for improving OA treatment.
Main Methods:
- Fabrication of a dopamine-coated antibody-Au (core)-Ag (shell) SERS sensor for MIF detection.
- Optimization of experimental conditions to achieve high sensitivity and a wide linear range for MIF quantification.
- Validation of the sensor using 40 clinical PRP samples and comparison with Enzyme-Linked Immunosorbent Assay (ELISA).
Main Results:
- The developed SERS sensor demonstrated an ultrasensitive detection limit of 90.05 pg/mL for MIF.
- A good linear relationship was observed between MIF concentrations ranging from 1-5000 ng/mL.
- MIF concentrations in clinical PRP samples ranged from 2.0-3.6 ng/mL, with results consistent with ELISA.
Conclusions:
- The novel SERS sensor provides a highly sensitive, rapid, and cost-effective method for MIF detection in PRP.
- This technology has the potential to significantly improve sample quality and maximize the therapeutic effect of PRP for OA treatment.
- The sensor offers advantages over traditional ELISA, including lower cost, shorter testing time, and reduced sample consumption.
